Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BLRX |
---|---|---|
09:32 ET | 1143 | 0.63 |
09:50 ET | 147 | 0.630001 |
09:59 ET | 100 | 0.64 |
10:01 ET | 1000 | 0.6201 |
10:17 ET | 5000 | 0.62 |
10:28 ET | 3000 | 0.62025 |
10:32 ET | 4250 | 0.6299 |
10:55 ET | 487 | 0.6202 |
10:57 ET | 4100 | 0.6299 |
11:00 ET | 5000 | 0.6299 |
11:02 ET | 2000 | 0.62286 |
11:04 ET | 222 | 0.6299 |
11:08 ET | 222 | 0.6211 |
11:13 ET | 8031 | 0.63 |
11:15 ET | 8100 | 0.63 |
11:42 ET | 1600 | 0.625 |
11:58 ET | 12000 | 0.63 |
12:03 ET | 100 | 0.6254 |
12:16 ET | 300 | 0.6255 |
12:34 ET | 772 | 0.629999 |
12:39 ET | 438 | 0.629447 |
01:15 ET | 100 | 0.6255 |
01:17 ET | 1000 | 0.6256 |
01:21 ET | 7477 | 0.62 |
01:37 ET | 1100 | 0.6113 |
01:39 ET | 175 | 0.6114 |
01:46 ET | 350 | 0.6115 |
01:48 ET | 3500 | 0.62 |
01:50 ET | 2500 | 0.6199 |
02:00 ET | 2703 | 0.62 |
02:04 ET | 100 | 0.63 |
02:06 ET | 3000 | 0.63 |
02:22 ET | 2000 | 0.6299 |
02:26 ET | 3000 | 0.6201 |
02:42 ET | 315 | 0.6201 |
03:03 ET | 2650 | 0.63 |
03:14 ET | 3200 | 0.6299 |
03:34 ET | 500 | 0.627 |
03:38 ET | 16704 | 0.63 |
03:45 ET | 368 | 0.63 |
03:48 ET | 2000 | 0.63 |
03:54 ET | 53454 | 0.644 |
03:57 ET | 500 | 0.633 |
03:59 ET | 1191 | 0.6211 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
BioLine RX Ltd | 54.9M | -0.8x | --- |
Kronos Bio Inc | 57.3M | -0.5x | --- |
LAVA Therapeutics NV | 45.2M | -1.9x | --- |
Atara Biotherapeutics Inc | 55.0M | -0.2x | --- |
Kezar Life Sciences Inc | 41.6M | -0.4x | --- |
Armata Pharmaceuticals Inc | 82.3M | -1.2x | --- |
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.9M |
---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.